ArticleScientific reports2022

In situ vaccination using unique TLR9 ligand K3-SPG induces long-lasting systemic immune response and synergizes with systemic and local immunotherapy.

Hirokazu Okada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.